Fig. 2From: Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapyThe melittin-MIL-2 promoted the production of IFN-γ. a Representative IFN-γ ELISA for PBMCs cultured for 3 days with the melittin-MIL-2 (2 µM) or rIL-2 (2 µM) and melittin (2 µM) alone. PBMCs were obtained from 3 normal, healthy donors (Donor A, B, C). b When tested on isolated T cells (CD4+, CD8+) and NK cells, increase in IFN-γ production was observed in all cells treated with the melittin-MIL-2. *p < 0.01 compared to control (rIL-2 or melittin)Back to article page